Jacobsen N, Schäfer U, Ostendorf P, Kubaneck B, Wolf H
Tokai J Exp Clin Med. 1985 Jun;10(2-3):193-5.
In an attempt to reduce the incidence of lethal cytomegalovirus (CMV) interstitial pneumonitis after allogenic bone marrow transplantation 49 patients were randomized in a multicenter controlled study to receive either CMV-hyperimmune globulin or a control immune globulin with low anticytomegalovirus titer. Immune globulin was administered intravenously 6 times with 20 days interval, starting on day 7 before transplantation. Patients receiving CMV hyperimmune globulin or control immune globulin were comparable with regard to age, diagnosis, pretransplant anti-CMV titer, incidence of graft-versus-host disease and transfusions. In each group, the incidence of histologically proven CMV interstitial pneumonitis during the first 110 days post BMT was recorded. Six of 23 patients in the control group versus 1 of 26 in the CMV hyperimmune globulin group died of CMV interstitial pneumonitis (p less than 0.05). No significant effect on idiopathic pneumonitis or survival was observed.
为降低异基因骨髓移植后致死性巨细胞病毒（CMV）间质性肺炎的发生率，49例患者在一项多中心对照研究中被随机分组，分别接受CMV高免疫球蛋白或抗巨细胞病毒滴度低的对照免疫球蛋白。免疫球蛋白于移植前7天开始静脉注射，每隔20天注射1次，共注射6次。接受CMV高免疫球蛋白或对照免疫球蛋白的患者在年龄、诊断、移植前抗CMV滴度、移植物抗宿主病发生率和输血方面具有可比性。记录每组患者在骨髓移植后前110天内经组织学证实的CMV间质性肺炎的发生率。对照组23例患者中有6例死于CMV间质性肺炎，而CMV高免疫球蛋白组26例患者中有1例死于CMV间质性肺炎（P<0.05）。未观察到对特发性肺炎或生存率有显著影响。
